Document Detail

Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
MedLine Citation:
PMID:  19996066     Owner:  NLM     Status:  MEDLINE    
Hypertension is a common risk factor for peripheral arterial disease (PAD). Guidelines suggest treating PAD patients to a blood pressure <130/80 mm Hg; therefore, our objective was to explore whether attainment of this target blood pressure is associated with improved outcomes. We performed a post hoc analysis of the INternational VErapamil-SR/Trandolapril STudy, a randomized clinical trial, which included hypertensive patients with concomitant PAD and coronary artery disease. There were 2699 PAD patients followed for a mean of 2.7 years (60 970 patient-years). The primary outcome, all-cause death, nonfatal myocardial infarction, or nonfatal stroke, occurred in 16.3% of PAD patients versus 9.2% without PAD (adjusted hazard ratio: 1.26 [95% CI: 1.13 to 1.40]; P<0.0001). The primary outcome occurred least frequently among PAD patients treated to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg. PAD patients displayed a J-shape relationship with systolic blood pressure and the primary outcome, although individuals without PAD did not. PAD patients may require a different target blood pressure than those without PAD.
Anthony A Bavry; R David Anderson; Yan Gong; Scott J Denardo; Rhonda M Cooper-Dehoff; Eileen M Handberg; Carl J Pepine
Related Documents :
8517426 - Comparison of bisoprolol with atenolol for systemic hypertension in four population gro...
17309946 - Effect of spironolactone on blood pressure in subjects with resistant hypertension.
1729066 - Effects of long-term treatment with prazosin on left ventricular diastolic function in ...
1285936 - Comparative effects of nitrendipine and hydrochlorothiazide on calciotropic hormones an...
1777376 - The interactions between nisoldipine and two beta-adrenoceptor antagonists--atenolol an...
7015036 - Screening of angiotensin ii dependent hypertensive patients using a linear classifier.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-12-07
Journal Detail:
Title:  Hypertension     Volume:  55     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 Jan 
Date Detail:
Created Date:  2009-12-18     Completed Date:  2010-01-21     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  48-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Aspirin / therapeutic use
Blood Pressure / drug effects*
Coronary Artery Disease / complications*
Follow-Up Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypertension / complications,  drug therapy*,  physiopathology
Kaplan-Meier Estimate
Multicenter Studies as Topic
Outcome Assessment (Health Care) / methods,  statistics & numerical data
Peripheral Vascular Diseases / complications*
Randomized Controlled Trials as Topic
Grant Support
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; R16CO5Y76E/Aspirin
Comment In:
Curr Hypertens Rep. 2010 Apr;12(2):53-5   [PMID:  20424956 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis...
Next Document:  Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with di...